Industry Payments and Prescribing of Brand-Name Multiple Sclerosis Medications in Medicare

Key Points

• The study aims to investigate the relationship between industry payments to clinicians and the prescribing patterns of brand-name multiple sclerosis medications.
• Analyzed payments made to clinicians from the industry.
• Examined prescribing data for multiple sclerosis medications in Medicare.
• Compared uptake rates of brand-name versus generic medications.
• Industry payments were linked to reduced prescriptions of generic MS drugs.
• Patients faced increased costs due to higher brand-name medication uptake.
• The US health care system experienced elevated spending as a result.

Abstract